Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study

INTRODUCTION: During clinical trials, mirabegron, a β3-adrenoreceptor agonist, was associated with increased vital signs vs placebo in patients with overactive bladder. OBJECTIVE: The purpose of this study was to compare incidence rates of adverse cardiovascular (CV) outcomes following mirabegron or...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoffman, Veena, Hallas, Jesper, Linder, Marie, Margulis, Andrea V., Suehs, Brandon T., Arana, Alejandro, Phiri, Kelesitse, Enger, Cheryl, Horter, Libby, Odsbu, Ingvild, Olesen, Morten, Perez-Gutthann, Susana, Xu, Yihua, Kristiansen, Nina Sahlertz, Appenteng, Kwame, de Vogel, Stefan, Seeger, John D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280006/
https://www.ncbi.nlm.nih.gov/pubmed/34236595
http://dx.doi.org/10.1007/s40264-021-01095-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280006/
https://www.ncbi.nlm.nih.gov/pubmed/34236595
http://dx.doi.org/10.1007/s40264-021-01095-7

Ejemplares similares